Compare Davita Inc (DVA) vs Kimberly Clark Corp (KMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Kimberly Clark Corp — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while Kimberly Clark Corp trades at $97.82 (market cap $32.09B). The key difference: Kimberly Clark Corp is far larger — about 2.8× Davita Inc's market cap, and Kimberly Clark Corp pays a 5.31% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Kimberly Clark Corp for 93 Days on average.
| DVA | KMB | |
|---|---|---|
Market Cap | $11.28B | $32.09B |
Volume | 650,294 | 2,800,459 |
Sector | Health | Consumer Staples |
52-Week High | $240.96 | $121.44 |
52-Week Low | $103.87 | $93.05 |
Typical Hold Time | 113 Days | 93 Days |
Enterprise Value | $24.00B | $37.65B |
Dividend Yield | — | 5.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
Kimberly-Clark (KMB) trades at $97.74, up 1.0% on the day, with a bearish technical signal but strong dividend yield of 5.16%. Recent earnings show a mix of beats and a Q2 2026 miss, while the pending Kenvue acquisition and executive transitions dominate news. The stock is undervalued relative to its consensus price target of $117.25, with a P/E of 19.07 and robust profitability metrics including a net income margin of 11.79%.
KMB offers a high dividend yield and valuation upside, but risks include integration challenges from the Kenvue deal, cash flow pressures, and bearish technical trends. Analyst consensus is cautious with 61% hold ratings, reflecting concerns over execution and sustainability of the dividend amid acquisition-related liabilities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →
